3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 5, 1996, Pages 499-504

  Sit, Sing Yuen ^a   Ehrgott, Frederick J ^a   Gao, Jinnian ^a   Meanwell, Nicholas A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 2 QUINOLINONE DERIVATIVE; 5,7 DICHLORO 3 HYDROXY 2 OXOQUINOLINE 4 PYRUVIC ACID ETHYL ESTER; 5,7 DICHLOROKYNURENIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; GLYCINE; GLYCINE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; QUINOLINE DERIVATIVE; QUISQUALIC ACID; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; RAT; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

EID: 0029897886     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-894X(96)00031-5     Document Type: Article

References (21)

1. Meldrum, B. Cerebrovascular and Brain Metabolism Reviews, 1990, 2, 27.
2. (a) Cunningham, M. D.; Ferkany, J. W.; Enna, S.J. Life Sci. 1994, 54, 135.
3. (b) Danysz, W.; Parsons, C. G.; Bresink, I.; Quack, G. Drug News Persp. 1995, 8, 261.
4. (a) Leeson, P. D.; Iversen, L. L. J. Med. Chem. 1994, 37, 4053.
5. (b) Carter, A. J. Drugs Fut. 1992, 17, 595.
6. Leeson, P. D.; Baker, R.; Carling, R. W.; Curtis, N. R.; Moore, K. W.; Williams, B.J.; Foster, A. C.; Donald, A. E.; Kemp, J. A.; Marshall, G. R. J. Med. Chem. 1991, 34, 1243.
7. Salituro, F. G.; Harrison, B. L.; Baron, B. M.; Nyce, P. L.; Stewart, K. T.; Kehne, J. H.; White, H. S.; McDonald, I. A. J. Med. Chem. 1992, 35, 1791.
8. Sheardown, M. J.; Nielsen, E. O.; Hansen, A. J.; Jacobsen, P.; Honore, T. Science, 1990, 247, 571.
9. (a) Epperson, J. R.; Hewawasam, P.; Meanwell, N. A.; Boissard, C. G.; Gribkoff, V. K.; Post-Munson, D. Bioorg. Med. Chem. Lett. 1993, 3, 2801.
10. (b) Woodward, R. M.; Huettner, J. E.; Guastella, J.; Keana, J. F. W. and Weber, E. Mol. Pharmacol. 1995, 47, 568-581;
11. The isomeric 3-substituted-4-hydroxy quinoline derivatives have recently been described as potent glycine antagonists: Kulagowski, J. J.; Baker, R.; Curtis, N. R.; Leeson, P. D.; Mawer, I. M.; Moseley, A. M.; Ridgill, M. P.; Rowley, M.; Stansfield, I.; Foster, A. C.; Grimwood, S.; Hill, R. G.; Kemp, J. A.; Marshall, G. R.; Saywell, K. L. and Tricklebank, M. D. J. Med. Chem. 1994, 37, 1402-1405
12. Swartz, K. J.; Koroshetz, W. J.; Rees, A. H.; Huettner, J. E. Mol. Pharmacol. 1992, 41, 1130;
13. (a) Eistert, B.; Borggrefe, G. Annalen, 1968, 718, 143.
14. (b) Jones, G. "Quinolines", Part 1; Jones, G. Ed.: John Wiley & Sons, New York, 1977.
15. Ethyl diazoacetate was obtained from Aldrich and used as received.
16. (a) Heck, R. F. Acct. Chem. Res. 1979, 12, 146.
17. (b) Heck, R. F. Org. React. 1982, 27, 345.
18. Ethyl 3-diazo-2-oxopropionate was prepared as described by Gallucci, R. R; Jones, M., Jr. J. Org. Chem. 1985, 50, 4404.
19. Snell, L. D.; Marter, R. S.; Johnson, K. M. Eur. J. Pharm. 1988, 156, 105.
20. Murphy, D. E.; Snowhill, E. W.; Williams, M. Neurochem. Res. 1987, 12, 775.
21. i values were obtained from 7- or 14-point concentration-response curves, and were averaged from 2-7 experiments.